viewAvacta Group PLC

Avacta rises as it secures licensing deal with New England Biolabs for Affimer technology

The biotechnology firm said it had been collaborating with NEB to develop Affimers to combine with NEB’s reagents (a substance used for chemical analysis)

The Affimers can be used to modulate the performance of several of NEB's enzymes in response to temperature

Shares in Avacta Group Plc (LON:AVCT) were on the up in late-morning trading Wednesday after it signed a licensing deal with New England Biolabs (NEB), an enzyme discovery and production company, to commercialise its Affimer technology for use in life science research and diagnostic assays.

The biotechnology firm said it had been collaborating with NEB to develop Affimers to combine with NEB’s reagents (a substance used for chemical analysis).

WATCH: Avacta Group CEO Alastair Smith confident of licensing deals this year

Avacta has also identified Affimers that inhibit several of NEB’s proprietary enzymes to provide modulation of their activity in response to temperature.

Unlike alternative enzyme inhibitors, Affimers can be fine-tuned to switch at the right temperature without having a negative effect on the overall assay performance.

NEB was in the final stages of product testing and had agreed with Avacta the terms under which the combined product would be commercialised.

While the financial details of the agreement were not disclosed, Avacata said it would receive a royalty on product sales, which could begin as soon as 2019.

The company added that it expected to continue the collaboration with NEB to generate Affimer tools and inhibitors for other enzymes, enabling further product developments.

Alastair Smith, chief executive of Avacta, said the agreement further validated the Affimer technology and the company’s licensing business model, adding that the royalty licenses would “underpin the future high margin revenue from Affimer reagents”.

In a note to clients, analysts at City broker finnCap estimated that royalties would stand at around 10%, while also reiterating their 120p price target for the group.

Shares were up 2% at 25p.

--Adds share price and broker comment--

Quick facts: Avacta Group PLC

Price: 16.25 GBX

Market: AIM
Market Cap: £18.88 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from...



Investor Update: Immotion signs deal with Aspro Parks

Headlines from the Proactive UK newsroom. Immotion (LON:IMMO) is to put one of its virtual reality entertainment pods in Spanish leisure operator Aspro Parks’ Blue Planet Aquarium in Cheshire.  Aspro’s one of the largest European operators of leisure parks and centres with 68 locations...

1 week, 2 days ago

2 min read